Research details patterns of COVID and long COVID symptoms across 42,000 individuals

In a recent study posted to the medRxiv* pre-print server, researchers examined 42,000 participants from nine longitudinal studies conducted in the United Kingdom (UK) to analyze the prevalence of coronavirus disease 2019 (COVID-19) symptoms and characterize long COVID symptom patterns.

A number of symptoms that individuals with COVID-19 may experience also occur among those without SARS-CoV-2 infection. Therefore, it is crucial to carefully investigate the extent and length of time of persistence of these symptoms following COVID-19 recovery.

Study: Characterising patterns of COVID-19 and long COVID symptoms: Evidence from nine UK longitudinal studies. Image Credit: eamesBot / ShutterstockStudy: Characterising patterns of COVID-19 and long COVID symptoms: Evidence from nine UK longitudinal studies. ​​​​​​​Image Credit: eamesBot / Shutterstock

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

About the study

In the present study, researchers collated electronic health records (EHR) data from the longitudinal health and wellbeing program of the UK National core studies between July 2020 and September 2021. Since EHRs poorly capture COVID-19 symptom persistence, they performed coordinated standardized analyses across nine longitudinal studies. The study approach minimized the heterogeneity of datasets of all the included studies and their designs besides maximizing comparability.

The team considered the 'no COVID-19' category as the reference group and the 'COVID-19 in last 12 weeks' category as the baseline group. The third study group was 'COVID-19 > last 12 weeks.'  The researchers used a questionnaire to gather information regarding COVID-19 and its symptoms in all the study participants. The period of reporting of symptoms ranged between two weeks and two months in the included studies. In each study, participants reported the presence of symptoms,  whether or not attributable to any specific cause. Further, for each study, the researchers conducted latent class analyses (LCAs) of reported symptoms separately within each COVID-19 status indicator category derived previously.

Furthermore, they used random-effects meta-analysis to combine prevalences of symptoms within the core symptom set across studies. They also combined odds ratio (ORs) for COVID-19 symptoms within the core symptom set across studies using the same analytical method.

Study findings

People in the baseline group exhibited the highest prevalence of known COVID-19 symptoms, including cough, fever, and loss of smell and taste. Since the study compared nine studies simultaneously, variations in the participants' age and geography varied the prevalence of some symptoms across studies. In other words, the current study results had face validity. Across all three study groups, the prevalence of runny nose and sneezing did not seem to vary, indicating these symptoms were not COVID-19-specific.

Using the symptom clustering analyses, the authors found a maximum of two symptom patterns among any of the COVID-19 groups. Some previous studies have also similarly found two symptom patterns. Caspersen et al. observed two distinct patterns of post-acute COVID-19 symptoms, viz.,  neurocognitive and cardiorespiratory. Likewise, Peluso et al. observed two clusters of patients, one with high symptom prevalence and the other low, with symptoms collated into seven domains. A higher symptom burden was more common among individuals with COVID-19 in the last 12 weeks than with no COVID-19.

Heatmap of symptom probability differences comparing the two COVID-19 groups with the no COVID-19 group across all studies. NCDS: 1958 National Child Development Study; BCS1970: 1970 British Cohort Study; NS: Next Steps; MCS: Millennium Cohort Study; ALSPAC: Avon Longitudinal Study of Parents and Children. Notes: White cells indicate that the symptom was not asked about in in that study; ALSPAC results for “loss of smell or taste” are duplicated in the “loss of smell” and “loss of taste” cells; TwinsUK results for “confusion” are duplicated in the “difficulty concentrating” and “memory loss” cells.

Heatmap of symptom probability differences comparing the two COVID-19 groups with the no COVID-19 group across all studies. NCDS: 1958 National Child Development Study; BCS1970: 1970 British Cohort Study; NS: Next Steps; MCS: Millennium Cohort Study; ALSPAC: Avon Longitudinal Study of Parents and Children. Notes: White cells indicate that the symptom was not asked about in in that study; ALSPAC results for “loss of smell or taste” are duplicated in the “loss of smell” and “loss of taste” cells; TwinsUK results for “confusion” are duplicated in the “difficulty concentrating” and “memory loss” cells.

While the symptom burden among those who never had COVID-19 was also substantially high, it was higher among those who have had COVID-19. This finding highlighted the importance of a control group in the analyses of COVID-19 symptoms. In fact, a lack of appropriate controls often hinders evaluating symptoms specific to acute COVID-19 and long COVID.

The authors compared the symptoms in COVID-19 in the last 12 weeks and no COVID-19 groups to find that their symptoms characterized acute COVID-19 and ongoing symptomatic COVID-19. These symptoms were fever, muscle pain, loss of taste and smell, dry cough, fatigue, shortness of breath, and breathing difficulty. Furthermore, symptoms identified by comparing the COVID-19 > last 12 weeks and no COVID-19 groups resembled the characteristic symptoms of long COVID. Consistent with existing literature, these symptoms were shortness of breath, impaired cognition, chest pain, and fatigue. Previous clinical reviews and meta-analyses have identified similar symptoms characterizing long COVID; however, these studies did not have an appropriate control group, such as a 'no COVID-19' group accounting for reference population symptoms.

The current study relied on its participants to report their COVID-19 symptoms. The authors found a higher symptom burden was more common in females across all three study groups. It was likely due to differential reporting of similar symptoms between males and females or females having a higher symptom burden.

Conclusions

The study discerned symptoms characteristic of acute COVID-19 and long COVID. However, the study results did not support the notion that long COVID might be a conglomerate of multiple syndromes discernible by differences in symptom patterns. In fact, all the identified symptoms largely replicated those previously identified in the literature.

Nevertheless, it is essential to build and expand the evidence base of typical long COVID symptoms to help its timely diagnosis and provide better treatment to patients suffering from long COVID.

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

Journal references:

Article Revisions

  • May 13 2023 - The preprint preliminary research paper that this article was based upon was accepted for publication in a peer-reviewed Scientific Journal. This article was edited accordingly to include a link to the final peer-reviewed paper, now shown in the sources section.
Neha Mathur

Written by

Neha Mathur

Neha is a digital marketing professional based in Gurugram, India. She has a Master’s degree from the University of Rajasthan with a specialization in Biotechnology in 2008. She has experience in pre-clinical research as part of her research project in The Department of Toxicology at the prestigious Central Drug Research Institute (CDRI), Lucknow, India. She also holds a certification in C++ programming.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Mathur, Neha. (2023, May 13). Research details patterns of COVID and long COVID symptoms across 42,000 individuals. News-Medical. Retrieved on November 22, 2024 from https://www.news-medical.net/news/20220621/Research-details-patterns-of-COVID-and-long-COVID-symptoms-across-42000-individuals.aspx.

  • MLA

    Mathur, Neha. "Research details patterns of COVID and long COVID symptoms across 42,000 individuals". News-Medical. 22 November 2024. <https://www.news-medical.net/news/20220621/Research-details-patterns-of-COVID-and-long-COVID-symptoms-across-42000-individuals.aspx>.

  • Chicago

    Mathur, Neha. "Research details patterns of COVID and long COVID symptoms across 42,000 individuals". News-Medical. https://www.news-medical.net/news/20220621/Research-details-patterns-of-COVID-and-long-COVID-symptoms-across-42000-individuals.aspx. (accessed November 22, 2024).

  • Harvard

    Mathur, Neha. 2023. Research details patterns of COVID and long COVID symptoms across 42,000 individuals. News-Medical, viewed 22 November 2024, https://www.news-medical.net/news/20220621/Research-details-patterns-of-COVID-and-long-COVID-symptoms-across-42000-individuals.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Public trust in COVID-19 vaccine science influences vaccine uptake in the US